Literature DB >> 8065306

c-Myc cooperates with activated Ras to induce the cdc2 promoter.

T L Born1, J A Frost, A Schönthal, G C Prendergast, J R Feramisco.   

Abstract

Expression of c-myc with constitutively active mutants of the ras gene results in the cooperative transformation of primary fibroblasts, although the precise mechanism by which these genes cooperate is unknown. Since c-Myc has been shown to function as a transcriptional activator, we have examined the ability of c-Myc and activated Ras (H-RasV-12) to cooperatively induce the promoter activity of cdc2, a gene which is critical for cell cycle progression. Microinjection of expression constructs encoding H-RasV-12 and c-Myc along with a cdc2 promoter-luciferase reporter plasmid into quiescent cells led to an increase in cdc2 promoter activity approximately 30 h after injection, a period which coincides with the S-to-G2/M transition in these cells. Expression of H-RasV-12 alone weakly activated the cdc2 promoter, while expression of c-Myc alone had no effect. Mutants of c-Myc lacking either the leucine zipper dimerization domain or the phosphoacceptor site Ser-62 could not cooperate with H-RasV-12 to induce the cdc2 promoter. These mutants also lacked the ability to cooperate with H-RasV-12 to stimulate DNA synthesis. Deletion analysis identified a distinct region of the cdc2 promoter which was required for c-Myc responsiveness. Taken together, these observations suggest a mechanistic link between the molecular activities of c-Myc and Ras and induction of the cell cycle regulator Cdc2.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8065306      PMCID: PMC359096          DOI: 10.1128/mcb.14.9.5710-5718.1994

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  49 in total

1.  Abrogation by c-myc of G1 phase arrest induced by RB protein but not by p53.

Authors:  D W Goodrich; W H Lee
Journal:  Nature       Date:  1992-11-12       Impact factor: 49.962

2.  Max and c-Myc/Max DNA-binding activities in cell extracts.

Authors:  T D Littlewood; B Amati; H Land; G I Evan
Journal:  Oncogene       Date:  1992-09       Impact factor: 9.867

3.  Functional role for c-myc in mitogenic response to platelet-derived growth factor.

Authors:  H A Armelin; M C Armelin; K Kelly; T Stewart; P Leder; B H Cochran; C D Stiles
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

4.  Biological activities of v-myc and rearranged c-myc oncogenes in rat fibroblast cells in culture.

Authors:  E Mougneau; L Lemieux; M Rassoulzadegan; F Cuzin
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

5.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

6.  Sequence curiosity in v-myc oncogene.

Authors:  T S Papas; J A Lautenberger
Journal:  Nature       Date:  1985 Nov 21-27       Impact factor: 49.962

7.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.

Authors:  B Amati; S Dalton; M W Brooks; T D Littlewood; G I Evan; H Land
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

8.  Myc and Max proteins possess distinct transcriptional activities.

Authors:  L Kretzner; E M Blackwood; R N Eisenman
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

9.  Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals.

Authors:  E J Keath; P G Caimi; M D Cole
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

10.  Cell cycle regulation of the human cdc2 gene.

Authors:  S Dalton
Journal:  EMBO J       Date:  1992-05       Impact factor: 11.598

View more
  18 in total

1.  Transient expression of a winged-helix protein, MNF-beta, during myogenesis.

Authors:  Q Yang; R Bassel-Duby; R S Williams
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  Cell cycle and apoptosis.

Authors:  Katrien Vermeulen; Zwi N Berneman; Dirk R Van Bockstaele
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

Review 3.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

4.  A critical role for cyclin C in promotion of the hematopoietic cell cycle by cooperation with c-Myc.

Authors:  Z J Liu; T Ueda; T Miyazaki; N Tanaka; S Mine; Y Tanaka; T Taniguchi; H Yamamura; Y Minami
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

Review 5.  c-Myc target genes involved in cell growth, apoptosis, and metabolism.

Authors:  C V Dang
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

6.  Transfer of macromolecules into living adult cardiomyocytes by microinjection.

Authors:  M Bartoli; W C Claycomb
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

7.  The G1/S boundary-specific enhancer of the rat cdc2 promoter.

Authors:  M Shimizu; E Ichikawa; U Inoue; T Nakamura; T Nakajima; H Nojima; H Okayama; K Oda
Journal:  Mol Cell Biol       Date:  1995-05       Impact factor: 4.272

8.  In vivo structure of the human cdc2 promoter: release of a p130-E2F-4 complex from sequences immediately upstream of the transcription initiation site coincides with induction of cdc2 expression.

Authors:  S Tommasi; G P Pfeifer
Journal:  Mol Cell Biol       Date:  1995-12       Impact factor: 4.272

9.  GATA-1-mediated proliferation arrest during erythroid maturation.

Authors:  Marcin Rylski; John J Welch; Ying-Yu Chen; Danielle L Letting; J Alan Diehl; Lewis A Chodosh; Gerd A Blobel; Mitchell J Weiss
Journal:  Mol Cell Biol       Date:  2003-07       Impact factor: 4.272

Review 10.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.